Docket No.

218199US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Cristina GERONI, et al.

SERIAL NO:

New US PCT application based on PCT EP00 06540

GAU:

FILED:

Herewith

EXAMINER:

· FOR-

COMBINED PREPARATIONS COMPRISING ANTITUMOR AGENTS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number <u>15-0030</u>. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No.

24,618

Surinder Sachar

Registration No.

34,423



22850

Fax (703) 413-2220 (OSMMN 10 01)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPI	JCATION OF	Cristina	GERONI, et al

SERIAL NO. New US PCT application based on PCT EP00 06540

GAU:

FILED:

Herewith

EXAMINER:

FOR:

COMBINED PREPARATIONS COMPRISING ANTITUMOR AGENTS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number <u>15-0030</u>. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

periode facher

Norman F. Oblon

Registration No.

24,618


Surinder Sachar

Registration No.

34,423



Tel. (703) 413-3000 Fax. (703) 413-2220 OSMMN 10 01)



SERIAL NO. ATTY DOCKET NO. U.S. DEPARTMENT OF COMMERCE Form PTO 1449 New US PCT application PATENT AND TRADEMARK CIFFICE (Moditled) 218199US0PCT based on PCT/EP00/06540 **APPLICANT** LIST OF REFERENCES CITED BY APPLICANT Cristina GERONI, et al. GROUP FILING DATE Herewith **U.S. PATENT DOCUMENTS EXAMINER** DOCUMENT SUB FILING DATE CLASS DATE NAME CLASS IF APPROPRIATE INITIAL NUMBER 10/14/97 Michael H. SHEPARD et al. AA 5 677 171 ΑB 5 705 157 01/06/98 Mark I. GREENE AC ΑD ΑE ΑF ΑG ΑH ΑI AJΑK ALΑM ΑN FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY NUMBER YES NO 00 69460 11/23/00 WO No AO No 99 31140 06/24/99 WO AP AQ 00 44225 08/03/00 WO No 10/19/00 AR 00 61185 WO No No AS 89 06692 07/27/89 WO AT 0 328 147 08/16/89 EP No ΑU ΑV OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) J. BASELGA et al.: "HER2 Overexpression and Paclitaxel sensitivity in breast cancer: Therapeutic implications" AW ONCOLOGY, CH, S. KARGER AG, BASEL, vol. 11, no. 3, suppl. 02, pages 43-48 03/97 Αλ ΑY ΑZ Additional References sheet(s) attached Date Considered Examiner *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.